Irlab Therapeutics is moving its oral candidate, IRL757, into a Phase 1b clinical study to assess its safety and explore early signs of efficacy in treating apathy in people with Parkinson’s disease. Patient enrollment is expected to begin in the second half of 2025. Financial support for the trial…
A rare mutation in the LRRK2 gene found in 17 individuals with Parkinson’s disease or a family history of Parkinson’s — all of European ancestry with a shared genetic background — appears to be a likely cause of the condition, according to a study of thousands of people. The…
Older adults with tremor are three times more likely than those in the general elderly population to develop Parkinson’s disease — especially if they act out their dreams while sleeping or experience new-onset rest tremor — a study from China has found. That study aimed “to explore predictive factors”…
Physical exercise eased signs of a type of iron-mediated cell death called ferroptosis in microglia and improved neurological function in mouse models of Parkinson’s disease, a study finds. Microglia are a type of nervous system support cell that’s believed to be important in the neurodegenerative disease. When ferroptosis was…
The Michael J. Fox Foundation (MJFF) has brought together top experts from around the world to speed up research on five lesser-known biological targets in Parkinson’s disease in an effort to identify promising treatment opportunities. Seven more will be explored in a future phase. This effort is part…
NDC-0524, an experimental antibody that Nitrase Therapeutics is developing as a treatment for people with Parkinson’s disease, is expected to enter clinical testing in the fourth quarter of 2025, or before the end of the year, according to a company press release. The antibody, which targets nitrated…
Newronika is preparing for the commercial launch of AlphaDBS — a next-generation adaptive deep brain stimulation (DBS) system for treating Parkinson’s disease — at selected markets in Europe this year, following CE Mark approval in the European Union. That’s according to a company press release, in which…
Neuropacs‘ MRI-based artificial intelligence (AI) technology demonstrated 96% accuracy in distinguishing Parkinson’s disease from atypical parkinsonism — including multiple system atrophy, known as MSA, and progressive supranuclear palsy, called PSP — the company announced, detailing the results of a federally funded U.S. study. Moreover, the system achieved 98%…
Parkinson Italia — a network of 30 associations for patients and caregivers in Italy — is backing an initiative by the Prada Foundation that seeks to highlight the importance of prevention and early treatment of neurodegenerative diseases like Parkinson’s. The campaign, dubbed Preserving the Brain: A…
Parkinson’s disease can lead to early retinal changes — alterations in the thin layer at the back of the eye, known as the retina, that’s responsible for detecting light and sending visual signals to the brain — that can be revealed with the use of a simple eye test,…
Get regular updates to your inbox.
